December 20th 2024
Jason M Pogue, PharmD, BCPS, BCIDP discusses the findings, pharmacokinetics, why ceftolozane-tazobactam may be the preferred choice for resistant infections, and more.
November 11th 2024
VABOMERE Shows Higher Cure Rate in Patients with CRE Infections Vs. Best Available Therapy
October 18th 2017Michael N. Dudley, PharmD, explains how VABOMERE was associated with a higher overall cure rate and lower mortality compared with the best available therapy in patients with CRE infections in a recent trial.
Watch